NL-OMON24089招募中不适用
Phase I pharmacological study of continuous and intermittent chronomodulated capecitabine therapy
etherlands Cancer Institute - Antoni van Leeuwenhoek Hospital0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histological or cytological proof of cancer
- •2. Patient who might benefit from treatment with capecitabine, e.g. colon, breast, pancreatic and gastric cancer, ACUP;
排除标准
- •1. Dihydropyrimidine dehydrogenase (DPD) deficiency as assessed on the basis of DPYD IVS14+1G>A (DPYD*2A) and 2846A>T mutation analysis;
- •2. Women who are pregnant or breast feeding;
研究者
相似试验
招募中
不适用
Phase I pharmacological study of continuous and intermittent chronomodulated capecitabine therapymalignancies10027655cancerNL-OMON40756Antoni van Leeuwenhoek Ziekenhuis42
已完成
不适用
A study to evaluate the pharmacokinetic and pharmacodynamic equivalence of HSP-130 and United States-approved Neulasta (Registered Trademark) and European Union-approved Neulasta (Registered Trademark) administered as a single subcutaneous dose to healthy volunteers.The study will be conducted in healthy subjects. Neulasta is indicated for the treatment of cancer chemotherapy-induced neutropenia.Cancer - Any cancerACTRN12615001049561Hospira, Inc.150
已完成
不适用
A Phase 1 Study to Compare the Pharmacokinetics of CAL-101 Capsules to Tablets in Healthy Male Subjects.Blooddiseaseleukemia/lymophoma10047954NL-OMON35094Calistoga Pharmaceuticals Inc.15
已完成
不适用
Prospective pharmacokinetic study of continuous-infusional 5-FJPRN-UMIN000035580Keio University60
已完成
1 期
A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers/AHealthy male volunteersOther -ACTRN12605000782639Epitan Limited6